JP2018512863A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512863A5 JP2018512863A5 JP2017554329A JP2017554329A JP2018512863A5 JP 2018512863 A5 JP2018512863 A5 JP 2018512863A5 JP 2017554329 A JP2017554329 A JP 2017554329A JP 2017554329 A JP2017554329 A JP 2017554329A JP 2018512863 A5 JP2018512863 A5 JP 2018512863A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- binding
- hiv
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149460P | 2015-04-17 | 2015-04-17 | |
| US62/149,460 | 2015-04-17 | ||
| PCT/US2016/027979 WO2016168758A1 (en) | 2015-04-17 | 2016-04-15 | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512863A JP2018512863A (ja) | 2018-05-24 |
| JP2018512863A5 true JP2018512863A5 (enExample) | 2019-05-23 |
| JP6811723B2 JP6811723B2 (ja) | 2021-01-13 |
Family
ID=57126939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554329A Expired - Fee Related JP6811723B2 (ja) | 2015-04-17 | 2016-04-15 | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10570191B2 (enExample) |
| EP (1) | EP3283112A4 (enExample) |
| JP (1) | JP6811723B2 (enExample) |
| CN (1) | CN107847591B (enExample) |
| AU (1) | AU2016249404B2 (enExample) |
| CA (1) | CA2983034A1 (enExample) |
| HK (1) | HK1245675A1 (enExample) |
| WO (1) | WO2016168758A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CA2983034A1 (en) * | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| JP2021507717A (ja) * | 2017-12-18 | 2021-02-25 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ | 抗原結合性ポリペプチド |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| WO2019222104A1 (en) * | 2018-05-18 | 2019-11-21 | Macrogenics, Inc. | Optimized gp41-binding molecules and uses thereof |
| PE20210685A1 (es) | 2018-07-03 | 2021-04-08 | Gilead Sciences Inc | Anticuerpos que se dirigen al gp120 de vih y metodos de uso |
| EP3830108A4 (en) * | 2018-07-27 | 2022-08-10 | International AIDS Vaccine Initiative | Engineered antibodies to hiv env |
| WO2020056383A1 (en) * | 2018-09-13 | 2020-03-19 | Children's National Medical Center | Cells comprising antibodies against human immunodeficiency virus and methods of preparing and using the same |
| US12365722B2 (en) | 2018-10-19 | 2025-07-22 | University Of Maryland, College Park | Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope |
| WO2020105700A1 (ja) * | 2018-11-22 | 2020-05-28 | 富士レビオ株式会社 | 抗体コンジュゲート |
| CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
| WO2021007285A1 (en) * | 2019-07-08 | 2021-01-14 | California Institute Of Technology | Anti-hiv vaccine antibodies with reduced polyreactivity |
| EP4013792A4 (en) | 2019-08-15 | 2023-10-04 | IGM Biosciences Inc. | IMMUNO-STIMULATING MULTIMER BINDING MOLECULES |
| US20220363737A1 (en) * | 2019-09-26 | 2022-11-17 | Regents Of The University Of Minnesota | Nk engager compounds that bind viral antigens and methods of use |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| CA3187085A1 (en) | 2020-08-25 | 2022-03-03 | Manuel Baca | Multi-specific antigen binding molecules targeting hiv and methods of use |
| KR20220027785A (ko) * | 2020-08-27 | 2022-03-08 | 주식회사 셀리드 | 신규한 코로나바이러스 재조합 스파이크 단백질, 이를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터 및 상기 벡터를 포함하는 코로나바이러스감염증 예방 또는 치료용 백신 |
| CN113461811A (zh) * | 2021-06-30 | 2021-10-01 | 复旦大学 | 一种双特异性抗hiv-1抗体 |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| WO2025178915A1 (en) * | 2024-02-23 | 2025-08-28 | Icahn School Of Medicine At Mount Sinai | Multivalent protein complexes und uses thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| TW505656B (en) | 1995-12-18 | 2002-10-11 | Otsuka Pharma Co Ltd | Sugar-chain-recognizing antibodies and pharmaceutical composition for HIV infectious diseases |
| JP3463143B2 (ja) * | 1995-12-18 | 2003-11-05 | 秀親 岡田 | 糖鎖認識抗体及びｈｉｖ感染症治療剤 |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| DE19622088A1 (de) * | 1996-05-31 | 1997-12-04 | Boehringer Mannheim Gmbh | Anti-HIV-Antikörper als Kontrollproben |
| EP1015493A1 (en) * | 1997-01-10 | 2000-07-05 | EPIcyte Pharmaceutical, Inc. | Novel epithelial tissue targeting agent |
| JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク． | 治療薬としてのｃｄ１４７結合分子 |
| CN101016543A (zh) * | 2000-11-17 | 2007-08-15 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法 |
| CA2491859A1 (en) * | 2002-07-01 | 2004-01-08 | Hidechika Okada | Human igm antibody inducing apoptosis in hiv-infected cells and remedy for hiv-infection |
| US8980646B2 (en) * | 2003-03-26 | 2015-03-17 | Sudhir Paul | Proteolytic and covalent antibodies |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| US7513893B2 (en) * | 2004-03-12 | 2009-04-07 | Abraham Ebbie Soroudi | Device and method for treatment of eyelid diseases |
| CA2578613A1 (en) * | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| US20080038280A1 (en) | 2004-10-14 | 2008-02-14 | Government Of The United States Of America | A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines |
| JP2008519030A (ja) | 2004-11-05 | 2008-06-05 | パリンゲン インコーポレーテッド | 抗体で誘導される細胞膜損傷 |
| WO2006120230A2 (en) * | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| DK2112158T3 (da) | 2007-04-20 | 2012-01-23 | Hoffmann La Roche | Påvisning af primære infektioner med patogener |
| US20110236373A1 (en) * | 2008-09-25 | 2011-09-29 | Georgia Tomaras | Method of detecting antibodies and antibody-hiv virion complexes |
| JP5946766B2 (ja) * | 2009-07-03 | 2016-07-06 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | Ｈｉｖワクチン組成物における使用又は診断手段としての使用のためのｈｉｖ関連ペプチドの組合せ又は融合物 |
| WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
| CA2774636C (en) | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2533811A4 (en) | 2010-02-12 | 2013-12-25 | Res Corp Technologies Inc | MULTIMETER PROTEINS WITH IMMUNE LOBULIN CONSTANTS DOMAINS |
| WO2012106578A1 (en) * | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| WO2013049254A1 (en) | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
| WO2013070776A1 (en) | 2011-11-07 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing gp41 antibodies and their use |
| CN108676091B (zh) | 2011-12-08 | 2022-04-01 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
| WO2013110790A1 (en) * | 2012-01-26 | 2013-08-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vaccine compositions for hiv prevention and treatment |
| MX363819B (es) | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Uniones a cdim y sus usos. |
| EP2828294A1 (en) | 2012-03-23 | 2015-01-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2880057A4 (en) * | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
| US20150216973A1 (en) * | 2012-08-08 | 2015-08-06 | Network Immunology Inc.. | Method for the induction of an immune response |
| JP2014124186A (ja) * | 2012-12-26 | 2014-07-07 | Industrial Technology Research Institute | 多価抗体フラグメントおよびその三量体化複合体 |
| EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| AU2015206002B2 (en) | 2014-01-16 | 2020-06-11 | Mario Umberto Francesco MONDELLI | Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CA2983034A1 (en) * | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| CN109561681A (zh) | 2016-07-20 | 2019-04-02 | Igm生物科学股份有限公司 | 多聚gitr结合分子及其用途 |
| CA3030647A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| WO2018017761A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| AU2017299610B2 (en) | 2016-07-20 | 2022-09-29 | Igm Biosciences, Inc. | Multimeric CD40 binding molecules and uses thereof |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| CN111757941A (zh) | 2018-02-26 | 2020-10-09 | Igm生物科学股份有限公司 | 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途 |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| CA3113268A1 (en) | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | Multivalent igm- and iga-fc-based binding molecules |
| WO2020163646A1 (en) | 2019-02-08 | 2020-08-13 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
-
2016
- 2016-04-15 CA CA2983034A patent/CA2983034A1/en active Pending
- 2016-04-15 HK HK18105481.5A patent/HK1245675A1/zh unknown
- 2016-04-15 WO PCT/US2016/027979 patent/WO2016168758A1/en not_active Ceased
- 2016-04-15 CN CN201680035419.8A patent/CN107847591B/zh not_active Expired - Fee Related
- 2016-04-15 EP EP16780944.1A patent/EP3283112A4/en not_active Withdrawn
- 2016-04-15 US US15/566,485 patent/US10570191B2/en active Active
- 2016-04-15 JP JP2017554329A patent/JP6811723B2/ja not_active Expired - Fee Related
- 2016-04-15 AU AU2016249404A patent/AU2016249404B2/en not_active Ceased
-
2020
- 2020-01-07 US US16/736,327 patent/US11192941B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512863A5 (enExample) | ||
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| US12180302B2 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| US8168757B2 (en) | PD-1 binding proteins | |
| HRP20200583T1 (hr) | Protutijela koja neutraliziraju gp120 i njihova upotreba | |
| IL258822B2 (en) | Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection | |
| US10344077B2 (en) | HIV-1 neutralizing antibodies and uses thereof (V3 antibodies) | |
| KR20210075129A (ko) | 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법 | |
| JP2019530640A5 (enExample) | ||
| JP2019528683A5 (enExample) | ||
| DK2793945T3 (en) | USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION | |
| US20240336672A1 (en) | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof | |
| CN107108721B (zh) | 包含hiv-1包膜靶向臂的双特异性分子 | |
| CN103282385A (zh) | 用于hiv治疗的融合蛋白 | |
| JP2018512863A (ja) | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 | |
| RU2020130795A (ru) | Нейтрализующие антитела к env вич-1 и их применение | |
| CN115991778A (zh) | 抗pd-l1抗体及其用途 | |
| WO2017011413A1 (en) | Bispecific molecules comprising an hiv-1 envelope targeting arm | |
| TW202200620A (zh) | 抗flt3抗體及組合物 | |
| WO2020082045A1 (en) | Multispecfic anti-hiv antibodies | |
| WO2019199916A1 (en) | Fab-based trispecific antibodies | |
| US20220144956A1 (en) | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII | |
| US11059882B2 (en) | Anti-HIV dual specificity antibodies and methods of HIV treatment | |
| AU2019269383A1 (en) | Optimized GP41-binding molecules and uses thereof | |
| CA3136147A1 (en) | Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection |